BioAtla (BCAB) Liabilities and Shareholders Equity (2020 - 2025)

BioAtla's Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $4.3 million for Q4 2025.

• On a quarterly basis, Liabilities and Shareholders Equity fell 91.83% year-over-year to $4.3 million in Q4 2025; TTM through Mar 2026 was $47.3 million, a 78.64% decrease from a year earlier, with the FY2025 full-year figure at $4.3 million, down 91.83% from the prior year.
• Liabilities and Shareholders Equity retreated to $4.3 million in Q4 2025 per BCAB's latest filing, from $15.9 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $277.6 million in Q3 2021 and bottomed at $4.3 million in Q4 2025.
• The 5-year median for Liabilities and Shareholders Equity is $165.5 million (2023), against an average of $142.5 million.
• Across the five-year window, Liabilities and Shareholders Equity grew 3.87% in 2021 and sank 91.83% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $254.4 million in 2021, then dropped by 11.27% to $225.7 million in 2022, then plunged by 46.99% to $119.7 million in 2023, then sank by 56.19% to $52.4 million in 2024, then sank by 91.83% to $4.3 million in 2025.
• Per Business Quant, the three latest BCAB Liabilities and Shareholders Equity figures stand at $4.3 million (Q4 2025), $15.9 million (Q3 2025), and $27.1 million (Q2 2025).